The mechanism by which the FA activates PPARα to prevent NAFLD involves the following: Firstly, FA supplementation decreased hepatic TG accumulation via promoting fatty acid β-oxidation and ketone body biosynthesis to increase fatty acid expenditure. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.